MAMAH
Improving Maternal and Infant Health by reducing malaria risks in African women: evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women
- Duration
- 1/03/2018-28/02/2023
- Coordinator
- Clara Menéndez, ISGlobal
- Funded by
- EDCTP
- Website
- https://www.mamahproject.net
Malaria infection during pregnancy is an important driver of maternal and neonatal health especially among HIV infected women. In Africa, at least one million pregnancies are co-infected with malaria and HIV annually. The interaction between the two infections is particularly deleterious in pregnancy, leading to increased risk of malaria and HIV viral load, which may increase the frequency of mother to child transmission of HIV (MTCTHIV).
Intermittent preventive treatment in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) is recommended for malaria prevention in HIV-uninfected women but it is contraindicated in those HIV-infected on cotrimoxazole prophylaxis (CTXp) due to potential adverse effects. A recent EDCTP-funded trial showed that although an effective antimalarial (mefloquine) added to CTXp and long-lasting insecticide treated nets (LLITNs) in HIV-infected pregnant women improves malaria prevention and maternal health, it was not well tolerated and it was associated with an increase in HIV viral load at delivery and a two-fold increased risk of MTCT-HIV. Thus, this highlights the need to find alternative drugs with better tolerability and safety profile to prevent malaria in this vulnerable group and to further study the pharmacological interactions between antimalarial and antiretroviral (ARV) drugs.
Dihydroartemisinin-piperaquine (DHA-PPQ), has been shown to improve antimalarial protection in HIV-uninfected women constituting the most promising candidate for IPTp in HIV-infected pregnant women. However, there is limited information on the pharmacokinetics of DHA-PPQ with concomitant use of ARV drugs and CTX.
Objective
A randomized double blind placebo controlled trial to evaluate the safety and efficacy of DHA-PPQ for IPTp in HIV-infected pregnant women receiving CTXp and ARV drugs and using LLITNs will be conducted in Gabon and Mozambique where malaria and HIV infection are moderate to highly prevalent. The possibility of a pharmacokinetic interaction between DHA-PPQ and ARV drugs will be assessed. Women will receive ARV therapy according to national guidelines and their infants will be followed until one year of age to evaluate the impact of DHA-PPQ on MTCT-HIV.
This 5-year project, funded by EDCTP and coordinated by ISGlobal in collaboration with the Centre de Recherches Médicales de Lambaréné (CERMEL, Gabon), the Manhiça Health Research Center/ Fundaçao Manhiça (CISM/FM, Mozambique), the Medical University of Vienna (MedUni Wien, Austria), the Bernhard Nocht Institut für Tropenmedizin (BNITM, Germany), and the Eberhard Karls Universitaet Tuebingen (EKUT, Germany) will provide conclusive evidence to reduce the burden of two of the most important poverty-related diseases (PRDs), in HIV-infected pregnant women exposed to malaria.
Total funding
2,985,000 €
“This project is part of the EDCTP2 programme supported by the European Union”
With the support of:
This project is part of the EDCTP2 programme supported by the European Union
Other projects
See Past ProjectsMA-CoV
Prevalence and impact of SARS-CoV-2 infection on maternal and infant health in African populations
COMBACTE
Combating Bacterial Resistance In Europe
GAMA
Development of Novel Gastrointestinal Biomarkers for Use in HIV Incidence Determination in a Sub-Saharan African Setting
Evaluation of Strategies for Yaws Eradication
Yaws eradication
Novel Marine Biomolecules against Biofilm (NoMorFilm)
Application to medical devices
COMBACTE-CARE
Combatting Bacterial Resistance in Europe - Carbapenem Resistance
INTE-AFRICA
Integrating and decentralizing diabetes and hypertension services in Africa
ICARIA
Improving Care through Azithromycin Research for Infants in Africa
PreFIT
Predicting the Future: Incipient Tuberculosis
Predicting the Future: Incipient Tuberculosis
Encuesta serológica Cendea de Cizur
Cendea de Cizur
Projecte de Recerca en Resposta Immunitària i Epidemiologia de Malalties Infeccioses
Conèixer la propagació. Entendre la protecció
ANTICOV
Large Clinical Trial in Africa on the Treatment of Mild Cases of COVID-19
Stool4TB
Evaluating a new stool based qPCR for diagnosis of tuberculosis in children and people living with HIV
TB-RECONNECT
Reconnecting Transmission to Global Tuberculosis Control by Mapping Pathogen Transmission Events to Host Infection Status
SToolNIH
Quantifiable stool-based TB PCR to Improve Diagnostics and Treatment Monitoring
ALIA - Las ciudades y la salud
Planificación urbana, medio ambiente y salud | Clima y salud | Resistencias Antimicrobianas
END-VOC
ENDing COVID-19 Variants Of concern through Cohort studies (END-VOC)
TwinAir
Digital Twins Enabled Indoor Air Quality Management for Healthy Living
Estudio de la propagación de bacterias y genes de resistencia a los antibióticos en el ciclo integral del agua, en el área metropolitana de Barcelona
Propagación de la resistencia en aguas
Nuevos complejos de oro (III) frente a bacterias multirresistentes
Project Code: DTS21/00004
Desarrollo de dos nuevas estrategias terapéuticas (inhibidores de bombas de expulsion y ARN antisentido) activos frente a bacterias mutliresistentes
Más allá de la supresión vírica del VIH: un cuarto noventa para mejorar la salud de personas viviendo con el VIH en España
Project Code: PI20/01654
ENDÈMIC
Community knowledge generation through scientific culture, urban ecology and art
EpiGen
Building Scalable Pathogen Genomic Epidemiology in Ethiopia
Hepatitis C Free Baleares
Eliminating hepatitis C on the Balearic Islands (Mallorca, Menorca and Ibiza): a study in governmental and non-governmental addiction service centres, a mobile methadone unit and a prison to test and link people who use drugs to HCV care.
FLAVOBAC
Nuevas moléculas de oro coordinadas con flavonoides contra bacterias patógenas multirresistentes prioritarias
Evaluación de la eficacia del ácido acetilsalicílico a dosis bajas en la prevención de los efectos maternos y perinatales adversos en mujeres embarazadas infectadas por el SARS-CoV-2
CaDMIA-plus
Continued validation of the minimally invasive autopsy for the investigation of the causes of death in infants, and establishment of a research and training center to study causes of death
MIBio
Identification of Prematurity and Pre-Eclampsia as Causes of Mortality
MULTIPLY
MULTIple doses of IPTi Proposal: a Lifesaving high Yield intervention
IPERVAC-SL
Impact of perceptions of COVID-19 vaccines on health-seeking behaviours in Sierra Leone
RESPIRE
Respiratory syncytial virus (RSV) in African pregnant women and children
VITAL
Towards preparedness for new maternal vaccinations: Understanding barriers and facilitators to maternal vaccine acceptance
SARA (SARS-CoV-2 and Acetylsalicylic acid)
Efficacy of low dose acetylsalicylic acid in preventing adverse maternal and perinatal outcomes in SARS-CoV-2 infected pregnant women
HIV drug resistance (HIVDR)
Description of HIV drug resistance patterns and its association with the risk of HIV mother to child transmission among pregnant women from southern Mozambique
PROTECT
PReparing for Optimal Phase III/IV maTErnal Group B StreptococCal vaccine Trials in Africa